


Sun Pharma’s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint
Read More
Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata
Read More
Sun Pharma Brings Back Its #SecondBirthDate Campaign on National Doctors’ Day
Read More
Recent Comments